#bispecific

Mesothelin (MSLN) is a cell-membrane-anchored glycoprotein overexpressed in several cancers including pancreatic cancer, ovarian cancer, and mesothelioma. MSLN is protease-cleaved at the membrane-proximal region, releasing shed MSLN (sMSLN) into the tumor microenvironment, leaving behind a membrane-bound stub. sMSLN in the tumor microenvironment is hypothesized to create a ‘sink’ that could limit…

Among the most aggressive and resistant tumors of the central nervous system, glioblastoma (GBM) has a poor prognosis and few available treatments. Because of the tumor’s infiltrative nature, immunosuppressive environment, and resistance mechanisms, traditional treatments such as radiotherapy, chemotherapy, and surgery offer only modest survival benefits. Bispecific T-cell engagers (TCEs) have…

Among the most aggressive and resistant tumors of the central nervous system, glioblastoma (GBM) has a poor prognosis and few available treatments. Because of the tumor’s infiltrative nature, immunosuppressive environment, and resistance mechanisms, traditional treatments such as radiotherapy, chemotherapy, and surgery offer only modest survival benefits. Bispecific T-cell engagers (TCEs) have…

Bispecific T cell engagers (TCEs) often exhibit limited efficacy in solid tumors, in part due to immunosuppressive cues in the tumor microenvironment and low expression of targetable tumor antigens. Therapeutic strategies to improve TCE target sensitivity and enhance T cell effector functions therefore have significant translational potential. Here, we engineered TCEs that induce T cell…

The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS Summary AFM28, a bispecific innate cell engager targeting CD123 and CD16A, demonstrates promising results in eliminating leukemic stem and progenitor cells (LSPCs) expressing CD123 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). By engaging natural killer (NK) cells…

GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series Summary This case series highlights a newly recognized side effect of talquetamab, a GPRC5D-targeting bispecific antibody used to treat multiple myeloma: a distinct dizziness-ataxia syndrome. The study details the clinical presentation, characterized by balance impairment…

Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy Summary Nanobody-based bispecific antibody engagers offer a promising avenue for cancer immunotherapy. These molecules combine the target specificity of nanobodies, small and stable antibody fragments, with the ability to simultaneously engage immune cells and tumor cells. By targeting immune…

Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses Summary Genetically engineered CAR-T cells can be modified to secrete bispecific killer cell engagers (BiKEs) targeting both tumor-associated antigens and NK cell activating receptors. This innovative approach, known as BiKE-secreting CAR-T cells, effectively redirects NK cell…